GlassScriptPhysician profile
Daniel R Herleth
NPI 1235365776
$1,991.71
in general payments reported to CMS, 2019-2025
27 companies · $37.34 in 2025
The $37.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $119 · 2022: $370 · 2023: $522 · 2024: $351 · 2025: $37.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $277.82 | 2019-2023 | |
| Glaxosmithkline, LLC. | $276.28 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $149.53 | 2019-2020 | |
| Medtronic, INC. | $137.77 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Novo Nordisk INC | $137.73 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $113.89 | 2019-2024 | |
| Amgen INC. | $98.38 | 2019-2024 | Otezla, Repatha |
| Lilly USA, LLC | $94.11 | 2019-2023 | Mounjaro |
| Abbvie INC. | $92.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.30 | 2019-2024 | Ofev, Jardiance, Tradjenta |
| Abbott Laboratories | $79.17 | 2022-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $65.75 | 2019-2024 | Xarelto |
| Dexcom, INC. | $51.41 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $48.83 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $40.45 | 2019-2023 | Fasenra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $33.32 | 2022-2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.01 | 2023-2024 | Xifaxan |
| Boston Scientific Corporation | $23.90 | 2020 | |
| Edwards Lifesciences Corporation | $21.46 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Allergan, INC. | $20.91 | 2020 | |
| Neurocrine Biosciences, INC. | $18.49 | 2024 | Ingrezza |
| Phadia US INC. | $18.41 | 2023 | Immunocap |
| E.R. Squibb & Sons, L.L.C. | $17.74 | 2024 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $16.26 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.35 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Herleth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.